Stock Commentary - New York week to April 13, 2009
15 April 2009
NEW YORK: equities gyrated wildly in the holiday-shortened week to April 13, slumping at the start of the period on worries about the outlook for first quarter results However, there was a surge of 3.1% in the Dow Jones on April 9, taking the index back over the 8,000 level. Sentiment was helped by the first batch of figures looking positive. Pharmaceutical and biotechnology stocks were mixed, with 17 of those tracked rising and 19 falling.
However, the biggest gains to be seen were not among drug majors, all of which, barring Abbott Laboratories, up 2.4%, saw week-on-week declines. The latter was one of the first in the sector to produce first-quarter results (see page 5), but this was too late to impact on its share movement for the reporting period. Par Pharma shot up 17.7%, helped by the news that its subsidiary Strativa had submitted a New Drug Application for generic Zofran (ondansetron) orally-dissolving film strips (see page 21). King Pharma, which rose 12.6%, benefited from being added to the recommended list of Goldman Sacks analyst Shibani Malhotra, who anticipates Food and Drug Administration approval by mid-year of the firm's Embeda, a pharmacological abuse-deterrent, extended-release morphine product candidate under development by its subsidiary Alpharma. This is despite concerns that the FDA is reluctant to clear opioid painkillers (see page 12). She put the stock on her conviction buy list, with a price targe of $10. Embeda combines an extended-release opioid agonist with sequestered naltrexone, an opioid antagonist. When the Embeda capsule is crushed, chewed or dissolved, which are common approaches abusers use to tamper with the product in order to gain euphoria, the naltrexone is released thereby significantly reducing the euphoric effect of the opioid. Going the other way was Vivus, which fell 10.5%, having seen some really wide swings over the past few weeks. Celgene was down for a second week, falling another 3.2% following a downgrade from analysts at Zacks Investment Research. Biogen Idec saw a great deal of activity, ending up 5.8%, as the firm continued to reject billionaire investor Carl Icahn's board nominations and rumors of a takeover bid from French drug major Sanofi-Aventis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
A Denmark-headquartered company that currently has a pipeline of three independent endocrinology rare disease product candidates in clinical development and is advancing oncology as its second therapeutic area of focus.
Stock Commentary - New York week to April 13, 2009
NEW YORK: equities gyrated wildly in the holiday-shortened week to April 13, slumping at the start of the period on worries about the outlook for first quarter results However, there was a surge of 3.1% in the Dow Jones on April 9, taking the index back over the 8,000 level. Sentiment was helped by the first batch of figures looking positive. Pharmaceutical and biotechnology stocks were mixed, with 17 of those tracked rising and 19 falling.
However, the biggest gains to be seen were not among drug majors, all of which, barring Abbott Laboratories, up 2.4%, saw week-on-week declines. The latter was one of the first in the sector to produce first-quarter results (see page 5), but this was too late to impact on its share movement for the reporting period. Par Pharma shot up 17.7%, helped by the news that its subsidiary Strativa had submitted a New Drug Application for generic Zofran (ondansetron) orally-dissolving film strips (see page 21). King Pharma, which rose 12.6%, benefited from being added to the recommended list of Goldman Sacks analyst Shibani Malhotra, who anticipates Food and Drug Administration approval by mid-year of the firm's Embeda, a pharmacological abuse-deterrent, extended-release morphine product candidate under development by its subsidiary Alpharma. This is despite concerns that the FDA is reluctant to clear opioid painkillers (see page 12). She put the stock on her conviction buy list, with a price targe of $10. Embeda combines an extended-release opioid agonist with sequestered naltrexone, an opioid antagonist. When the Embeda capsule is crushed, chewed or dissolved, which are common approaches abusers use to tamper with the product in order to gain euphoria, the naltrexone is released thereby significantly reducing the euphoric effect of the opioid. Going the other way was Vivus, which fell 10.5%, having seen some really wide swings over the past few weeks. Celgene was down for a second week, falling another 3.2% following a downgrade from analysts at Zacks Investment Research. Biogen Idec saw a great deal of activity, ending up 5.8%, as the firm continued to reject billionaire investor Carl Icahn's board nominations and rumors of a takeover bid from French drug major Sanofi-Aventis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze